Why Are Drugs So Expensive? Learning About the Drug Development Process
|
|
- Henry Booker
- 8 years ago
- Views:
Transcription
1 Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal Use Only and cannot be transferred, reproduced or resold in whole or in part. No other rights are transferred with the purchase of this product. This product is a guide only and is not meant to take the place of regulatory, legal, or scientific counsel on the various aspects of drug discovery and development. Seventh Street Development Group PO Box 526, Lafayette, IN Phone: , info@seventhstreetdev.com
2 Why Are Drugs So Expensive? Page 2 of 92 Table of Contents Chapter 1 Introduction 3 Chapter 2 Overview of the Process 4 Chapter 3 Drug Discovery 7 Chapter 4 Preclinical Studies 16 Chapter 5 IND Submission 29 Chapter 6 Clinical Trials 33 Chapter 7 NDA Submission 38 Chapter 8 Phase IV Clinical Trials 46 Chapter 9 Generic Drugs 48 Chapter 10 Patents 54 Chapter 11 What's Next 61 Appendices 68 Glossary 83 References 86
3 Why Are Drugs So Expensive? Page 3 of 92 Chapter 1 Introduction Why are drugs so expensive? Millions of Americans are having problems affording essential and life-saving medicines. Healthcare prescription programs will only cover certain medications, making life even harder. Why is this all so costly and difficult? There are a variety of reasons for the current state of affairs, such as: -the drug development process -regulatory aspects of drug manufacture -the cost of getting a drug on the market -patent lifetimes covering the drugs -sales and marketing costs -etc In this book, we will go through the drug development process in the United States to give you an idea of what is involved in getting a new drug to the market. We will not cover every detail, but will try to give an overview of what is involved in getting a new drug on the market and will concentrate on pills and capsules, although other products will be mentioned. We think it will surprise you to learn how complex the process actually is, and it will give you a perspective on all the work that has gone into that pill or capsule that you are taking. We will also cover additional topics, such as generic drugs and patents, so you can understand that once a drug is on the market, there are still many changes that can occur which will affect the pricing of the drug. So let's get started...
4 Why Are Drugs So Expensive? Page 4 of 92 Chapter 2 Overview of the Process Companies try a variety of approaches to find new drugs and this is usually called the Drug Discovery phase. Once a drug candidate shows promise, it heads into Drug Development. Drug Development involves getting an Initial New Drug (IND) application approved by the FDA and then moving into three stages of human clinical trials. If a drug makes it through the clinical trials, a New Drug Application (NDA) must be approved before the product can be marketed. Typically a time frame of years is needed for a new experimental drug to be developed and approved in the US. It is estimated that out of every 5,000 compounds in Discovery, only five will make it into Drug Development and human testing. Only one of these five will be approved and marketed. Not very good odds! The following graphic helps show the stages and approximate timing of the overall process. Figure 1: Overview of the Drug Development Process (Source: Pharmaceutical Research and Manufacturers of America, Once a new drug makes it to the market, additional testing may be needed to determine any issues that may not have been detected during the clinical trials; this is called Phase IV. Even though extensive testing is done in healthy volunteers and people with the disease before the drug is approved, not all side effects may be found due to the diversity of the human population.
5 Why Are Drugs So Expensive? Page 5 of 92 It is estimated that $800 million dollars [1] was spent for each new drug that made it to market in This cost has increased dramatically over the years as shown in Figure 2. Expenditures per Rx Drug (Millions of 2000 Dollars) $900 $800 $700 $600 $500 $400 $300 $200 $100 $0 $138 $318 $ Figure 2: Increasing cost of drug development. [1] (Graphic from To put the drug development process in perspective, many of the new drugs that came on the market in 2007 were in discovery or early development around Many of the drugs currently in discovery today will not be available to patients for another dozen years. Talk about a long lead time! There are three requirements for approval of a new drug: 1. the drug is safe 2. it is effective in treating the disease 3. it can be manufactured correctly and reproducibly each time This sounds straightforward, but actually involves years of testing and research on compounds that no one has any prior experience with. Knowing what is involved in getting a new drug to the marketplace will help you understand why it takes so long and why so many drugs don't make it. It is a complex process that involves many scientific disciplines and many parts of a company or many companies working together to get that one success story on the market to help patients.
6 Why Are Drugs So Expensive? Page 6 of 92 Fun Facts about the Drug Development Process We will end this chapter with some facts from 1 = Number of new medicines that result from every 5,000-10,000 compounds screened [2] = Number of years required to make a medicine [3] 80,000 = Number of scientists researching new medicines in America's pharmaceutical companies [4] $58,800,000,000 = Spending on research and development of new medicines by pharmaceutical companies in 2007 [5] $1,300,000,000 = Average cost to develop one medicine. This amount is up from $138 million in 1975, $318 million in 1987, and $802 million in 2000 (2005 dollars) [6] 2 out of 10 = Number of new medicines that produce revenues that match or exceed average research and development costs [7] over 2,700 = Number of medicines in development [8] nearly 350 = Number of new medicines approved between 1997 and 2006 [9] nearly 250 = Number of medicines to treat rare diseases (affecting fewer than 200,000 in the U.S.) approved by the FDA in the last two decades [10] $4.44 = Amount saved in hospital costs for every $1 spent on medicines [11] 50-60% = Portion of cancer survival increases attributable to new medicines [12] 70% = Decrease in AIDS death rate since advent of new medicines in 1995 [13] 10 = Portion of every dollar spent on health care that goes to prescription medicines [14] = Years of effective patent life for medicines - about 6-7 years shorter than other products [15]
GAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationMSc program Pharmaceutical Design and Engineering. Peter Heegaard, Head of Studies DTU Veterinary
MSc program Peter Heegaard, Head of Studies DTU Veterinary There is a need for Pharma graduates Pharma industry in its widest sense (see next slide) Research institutions (public and private) Consultants
More informationCareers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA
PharmaSUG 2014 Paper CP07 Careers in Biostatistics and Clinical SAS Programming An Overview for the Uninitiated Justina M. Flavin, Independent Consultant, San Diego, CA ABSTRACT In the biopharmaceutical
More informationGoals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationTargeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
More informationValuation of Your Early Drug Candidate. By Linda Pullan, Ph.D. www.sharevault.com. Toll-free USA 800-380-7652 Worldwide 1-408-717-4955
Valuation of Your Early Drug Candidate By Linda Pullan, Ph.D. www.sharevault.com Toll-free USA 800-380-7652 Worldwide 1-408-717-4955 ShareVault is a registered trademark of Pandesa Corporation dba ShareVault
More informationPRESCRIPTION MEDICINES: COSTS IN CONTEXT
PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationIncome From Properly Structured Trials Can Be Exempt From Taxation, Attorneys Say
Income From Properly Structured Trials Can Be Exempt From Taxation, Attorneys Say (BNA Health Law Reporter, Dec. 9, 2010) Academic medical centers (AMCs) that conduct clinical drug trials have strong arguments
More informationWaiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
More informationHow Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA
How Public-Private Partnerships Benefit All Stakeholders Douglas C. Throckmorton, MD Deputy Director for Regulatory Programs, CDER, FDA September 10, 2013 Outline Need for improved science in support of
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationBIOPHARMACEUTICAL INDUSTRY IMPACT REPORT: Florida PRESENTED BY:
BIOPHARMACEUTICAL INDUSTRY IMPACT REPORT: Florida PRESENTED BY: About the report About PhRMA The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country s leading innovative
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationThe 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationThe Health Care Law: How It Can Help People With Cancer and Their Families
The Health Care Law: How It Can Help People With Cancer and Their Families The new health care law can help save lives from cancer. Learn how it could help you and the people you love. America has some
More informationScott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry
Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is
More informationQ3 2015 Financial Results and Corporate Update. November 4, 2015
Q3 2015 Financial Results and Corporate Update November 4, 2015 Introductions and Forward- Looking Statements Silvia Taylor, SVP Investor Relations and Corporate Affairs Agenda Introductions and Forward-Looking
More informationthe solution. I think too much of the health care issues we re faced with as opposed to the problem.
Introduction: Hi I m Sherrie Bossing and I manage Lilly s corporate brand and volunteer strategy worldwide. I m joined today with Dr. Jack Harris who is the Vice President responsible for US Medical Division,
More informationRichard T. Clark Chief Executive Officer and President. Executing on Our Strategy
Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERS
More informationPharmaPendium. The definitive source of best-in-class drug information
Please contact us for more information Americas E-Customer Service 360 Park Avenue South New York, NY 10010-1710 USA Tel: +1 888 615 4500 (+1 212 462 1978, if calling from outside the USA and Canada) Fax:
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationPharmaceutical Sciences
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aapspharmaceutica.com/students How do I know if a career in the pharmaceutical sciences
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More information2019 Healthcare That Works for All
2019 Healthcare That Works for All This paper is one of a series describing what a decade of successful change in healthcare could look like in 2019. Each paper focuses on one aspect of healthcare. To
More informationDrug Development Models in China and the Impact on Multinational Pharmaceutical Companies
Drug Development Models in China and the Impact on Multinational Pharmaceutical Companies By Ling Su, Ph.D. China represents a huge potential opportunity for the pharmaceutical industry in both commercial
More informationStephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015
Life Sciences Industry in Canada Stephen Dibert Global Practice Lead Life Sciences Foreign Affairs, Trade and Development Canada JBA Seminar - February, 2015 Life Sciences in Canada Canadian life sciences
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationThe Product Review Life Cycle A Brief Overview
Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review
More informationWhen treating a disease is bad business: orphan and neglected diseases
When treating a disease is bad business: orphan and neglected diseases Rocío Acuña Hidalgo Introduction Over the past decades, the development of thousands of new drugs to treat diseases has improved the
More informationDrug Development Process
Drug Development Process Original Arthur: Addie D. Anderson CRB Consulting Engineers, Inc. Overview Important milestones establishing our current system of regulations Step-by-step overview of the drug
More informationCenterWatch. volunteering. clinical trial. for a. www.centerwatch.com
volunteering for a clinical trial www.centerwatch.com :: about this pamphlet This pamphlet provides an overview of the clinical trials process and answers frequently asked questions that many potential
More informationExtemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationHealthcare Costs in the USA. They do things big over here
2 Prologue Healthcare Costs in the USA They do things big over here 4 Spending 5 Spending Societal Implications Medical expenses involved in 62% of all bankruptcies. Costs negate average wage increase
More informationClinical Trials: What You Need to Know
Clinical Trials: What You Need to Know Clinical trials are studies in which people volunteer to test new drugs or devices. Doctors use clinical trials to learn whether a new treatment works and is safe
More informationClinical Trials. Clinical trials the basics
Clinical Trials Clinical Trials This brochure is for people making decisions about cancer treatment. You may be thinking about a clinical trial for you or your child but need to know more before you decide.
More informationHOSPITAL DRUG SHORTAGES
HOSPITAL DRUG SHORTAGES OVERVIEW More than 45,000 different prescription drug products are on the market today, originating from about 1,400 different manufacturers. Each year, the U.S. experiences a shortage
More informationTERM SHEET EXAMPLE. 1 P age
1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with
More informationillinois health insurance marketplace
illinois health insurance marketplace healthcare reform is coming. find answers here. healthcarereform.illinois.gov The Affordable Care Act. What it means for you. In March of 2010, the Affordable Care
More informationNormand Laberge Vice-President Regulatory & Scientific Affairs Rx&D. Globalization of Clinical Research: Trends & Implications for Canada
Normand Laberge Vice-President Regulatory & Scientific Affairs Rx&D Globalization of Clinical Research: Trends & Implications for Success Rates by Phase and Therapeutic Area Source: Nature Reviews Drug
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationMontana Review: Specialty Tier Drugs
Montana Review: Specialty Tier Drugs November 7, 2014 Northwest Health Law Advocate Christina Goe, General Counsel Montana Office of the Commissioner of Securities and Insurance 1 The Problem Our office
More informationSafety Risk Management Company Perspective
Safety Risk Management Company Perspective Akihisa Harada, MD, Ph.D VP, Development Japan Pfizer Japan Inc. R&D Head Club Agenda REMS in FDAAA Safety Risk Management throughout a Drug s Lifecycle Risk
More informationIs it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
More informationIt goes by many names: Patient Protection and Affordable Care Act (PPACA) or ACA or Obama Care or simply Healthcare Reform.
WHAT IS HEALTHCARE REFORM? Healthcare Reform (HCR) is a law passed by Congress that provides many different requirements. A very important aspect of the law is that it is designed to provide individuals
More informationA COORDINATED SCREENING AND MANAGEMENT SYSTEM FOR EFFECTIVE LARGE-SCALE LITERATURE MONITORING
A COORDINATED SCREENING AND MANAGEMENT SYSTEM FOR EFFECTIVE LARGE-SCALE LITERATURE MONITORING MEETING PHARMACOVIGILANCE AND MEDICAL DEVICE POST-MARKET SURVEILLANCE REQUIREMENTS CONTENTS 1. The fundamentals
More informationMesothelioma. Information for Patients and Families. identifying and evaluating experimental
Mesothelioma CLINICAL TRIALS Information for Patients and Families identifying and evaluating experimental treatments table of contents Pg. 2... Phases of a Clinical Trial Pg. 3... Mesothelioma and Clinical
More informationCLINICAL TRIALS WITH MEDICINES IN EUROPE
CLINICAL TRIALS WITH MEDICINES IN EUROPE REGULATORY FRAMEWORK FOR CLINICAL TRIALS WITH MEDICINES IN EUROPE The pharmaceutical industry is the most highly regulated sector in Europe. The Commission has
More informationHOT TOPICS IN IN HEALTH CARE REFORM
By Felicia Fuller Publications Manager, DAC Patient Recruitment Services The Patient Protection and Affordable Care Act (ACA), colloquially known as Obamacare, is in full effect and its impact is palpable
More informationPrinciples for Responsible Clinical Trial Data Sharing
Principles for Responsible Clinical Trial Data Sharing Our Commitment to Patients and Researchers Biopharmaceutical companies are committed to enhancing public health through responsible sharing of clinical
More informationDiscover more, discover faster. High performance, flexible NLP-based text mining for life sciences
Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge
More informationStrategies to Prepare for Meetings with the FDA. Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA
Strategies to Prepare for Meetings with the FDA Kim Colangelo Associate Director for Regulatory Affairs Office of New Drugs, CDER, FDA Topics for Discussion Who Are We? How Do We Interact Internally? Why
More informationThe Health Care Law and
The Health Care Law and p Faith leaders are trusted partners in local communities. You have a unique ability to reach people, especially the most vulnerable, with the tools and information they need to
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationApplications are accepted on a rolling basis.
The University of Michigan Health System Peking University Health Science Center Joint Institute for Translational and Clinical Research Clinical Trial Grant Processes Purpose The University of Michigan
More informationBUILDING A STRONGER SOCIETY SOCIAL IMPACT INVESTMENT February 2014 Submission in response to the Discussion Paper
BUILDING A STRONGER SOCIETY SOCIAL IMPACT INVESTMENT February 2014 Submission in response to the Discussion Paper ABOUT RESEARCH AUSTRALIA is an alliance of 160 members and supporters advocating for health
More information2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY
2015 CMR INTERNATIONAL PHARMACEUTICAL R&D EXECUTIVE SUMMARY AUGUST 2015 2 CMR FACTBOOK 2015 EXECUTIVE SUMMARY INTRODUCTION R&D productivity across the global biopharmaceutical industry is a well-documented
More informationAffordable Care Act Policy and Implementation Briefing
HEALTHCARE.GOV Affordable Care Act Policy and Implementation Briefing Family Planning Council s Reproductive Health Conference April 27, 2012 Joanne Corte Grossi,, MIPP Regional Director U.S. Department
More informationQuality by Design Concept
3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationA Guide to Clinical Trials
A Guide to Clinical Trials For young people with cancer and their parents Children s Cancer and Leukaemia Group www.cclg.org.uk Original booklet produced in conjunction with the CCLG Patient Advocacy Committee.
More informationEmergence of Compassionate Use programmes
Emergence of Compassionate Use programmes Rosanna Melchior, PharmD, MS IDRAC, Thomson Scientific Overview What is compassionate use (CU) Overview of CU in Europe Authorities and Sponsors Roles and Responsibilities
More informationFDA Fast Track and Priority Review Programs
Order Code RS22814 February 21, 2008 FDA Fast Track and Priority Review Programs Summary Susan Thaul Specialist in Drug Safety and Effectiveness Domestic Social Policy Division By statutory requirements
More informationInstitute for OneWorld Health
Institute for OneWorld Health a nonprofit pharmaceutical company Oxymoron no more: nonprofits can deliver medicines for the poor of the world January 10, 2005 Victoria Hale, PhD CEO, OneWorld Health The
More informationTABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.
1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed
More informationTIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials
TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials Pharmaceutical leader deploys TIBCO Spotfire enterprise analytics platform across its drug discovery organization
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationClinical research trials and insurance
Clinical research trials and insurance Information for people who are planning to take part in a clinical research trial January 2011 This information is subject to change depending on medical advances
More informationCERTIFICATE IN BASIC PHARMACEUTICAL DEVELOPMENT Focusing on the Business of Pharmaceuticals
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN BASIC PHARMACEUTICAL DEVELOPMENT Focusing on the Business
More informationFrom the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT 2217-01 Basic Concepts
RSPT 2217 & Principles Gardenhire Chapter 1; p. 1-10 From the Text Key Terms and page 2 Orphan Drugs Table 1-1; page 6 Abbreviations Table 1-2; page 8 Aerosolized Agents Table 1-3; page 9 Drug: Pharmacology:
More informationSpecialty Drug Hyperinflation:
Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System Specialty drugs 1 offer important hope for many patients with complex, hard-to-treat illnesses. While the price of specialty
More informationPfizer Oncology. Guest Expert: Louis Denis, MD Director of Clinical Research, Pfizer Oncology. www.wnpr.org. www.yalecancercenter.
Pfizer Oncology Guest Expert: Louis, MD Director of Clinical Research, Pfizer Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken Miller. I am Bruce
More informationAlternatives for Employee Health Care in Today s World of Health Insurance
Alternatives for Employee Health Care in Today s World of Health Insurance sponsored by NFIB Health Plans, Administered by JLBG Health WWW.NFIBHEALTHBENEFITS.COM 1-866-706-8028 Webinar Overview Learn about
More informationStrong support. Remaining concerns
EORTC opinion on the proposal for an EU Regulation on clinical trials on medicinal products for human use and the 7 th of June ENVI report on this proposal It is clear that the Commission and appointed
More informationEmerging Clinical Sites: India and China. Patrycja Doba, Clinical Research Coordinator
Emerging Clinical Sites: India and China Patrycja Doba, Clinical Research Coordinator Overview 1. Outsourcing trends in Pharmaceutical Industry 2. Reasons for outsourcing 3. The most outsourced activity
More informationThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for Everyone Individuals, Families, States, Taxpayers All Face Higher Costs Due to Rising Drug Prices Prescription drugs are one of the major drivers
More informationHow To Understand The Paediatric Regulation
Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View DGRA Annual Congress 2006 Bonn, 10. May 2006 Dr. Susanne Keitel Content PUMA The Future Background Legislative
More informationTestimony on Opioid Overdose Prevention. Daniel Raymond, Policy Director, Harm Reduction Coalition
Testimony on Opioid Overdose Prevention Daniel Raymond, Policy Director, Harm Reduction Coalition Presented on March 25, 2014 to the House Appropriations Subcommittee on Labor, Health and Human Services,
More informationFDA Center for Drug Evaluation and Research (CDER)
FDA Center for Drug Evaluation and Research (CDER) Strategic Plan 2013-2017 Table of Contents Section Page I. Introduction.. 3 II. CDER Mission and Basic Business Model.. 3 III. Stakeholder Considerations
More informationCERTIFICATE IN CLINICAL TRIAL MANAGEMENT
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN CLINICAL TRIAL MANAGEMENT Designed for Pharmaceutical
More informationGLOBAL ACCESS LICENSING FRAMEWORK
GLOBAL ACCESS LICENSING FRAMEWORK Every university-developed technology with potential for further development into a drug, vaccine, or medical diagnostic should be licensed with a concrete and transparent
More informationWhat Cancer Patients Need To Know
Taking Part in Clinical Trials What Cancer Patients Need To Know NATIONAL INSTITUTES OF HEALTH National Cancer Institute Generous support for this publication was provided by Novartis Oncology. Taking
More informationDepartment for Business, Innovation and Skills: Science and Innovation Strategy 2014 Response from Alzheimer s Research UK
Department for Business, Innovation and Skills: Science and Innovation Strategy 2014 Response from Alzheimer s Research UK 1. Introduction 1.1. Alzheimer s Research UK is the UK s leading dementia research
More informationEthical Issues Surrounding the Conduct of Pediatric Clinical Studies
Ethical Issues Surrounding the Conduct of Pediatric Clinical Studies Karsten A. Holm Saint Joseph s University Graduate Ethics Paper Competition, Fall 2013 (Word Count 3000) 1 Introduction The ethical
More informationTop Ten Things to Know About Stem Cell Treatments
Top Ten Things to Know About Stem Cell Treatments Many clinics that are offering stem cell treatments make claims about what stem cells can and cannot do that are not supported by our understanding of
More informationTitle: Department: Approved by:
Title: Department: Emergency Use of an Investigational Drug or Biological Product, or Unapproved Medical Device Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners
More informationCommunicating uncertainty about benefits and
Communicating uncertainty about benefits and harms of pharmaceutical products Lisa M. Schwartz, MD, MS Steven Woloshin, MD, MS The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth
More informationYahoo! and Online Advertising of Prescription Drugs David Zinman, Vice President 11.12.2009
Yahoo! and Online Advertising of Prescription Drugs David Zinman, Vice President 11.12.2009 Why is Yahoo! here? Our vision is to be the center of people s lives online, and we are. 158M unique users visited
More informationClinical Trial Protocol Development. Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group
Clinical Trial Protocol Development Developed by Center for Cancer Research, National Cancer Institute Endorsed by the CTN SIG Leadership Group Objectives The clinical trial protocol is the heart of any
More informationClinical Trials at PMH
Clinical Trials at PMH What You Need To Know UHN Patient Education Improving Health Through Education A Guide for Patients, Their Families and Friends in the PMH Cancer Program This information is to be
More informationCoventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company
Coventry Health Care of Georgia, Inc. Coventry Health and Life Insurance Company PRESCRIPTION DRUG RIDER This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health
More informationTemple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034. Phone: 267.468.8560 Fax: 267.468.
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034 Phone: 267.468.8560 Fax: 267.468.8565 POST-MASTER S CERTIFICATE in CLINICAL TRIAL MANAGMENT Designed for Pharmaceutical
More informationPharmD Postdoctoral Fellowship Program
Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the
More informationThe Health Care Law and
The Health Care Law and Office of the Regional Director Community Resource California-Based, extensive travel to NV, AZ, and HI. Day-to-day, week-to-week, month-to-month Educate the public on the benefits
More informationMaking Ontario a Preferred Location for Global Clinical Trials
Making Ontario a Preferred Location for Global Clinical Trials Clinical Trials Ontario Inaugural Strategic Plan 2012 2017 Strategic Plan Table of Contents LIST OF ABBREVIATIONS... 3 EXECUTIVE SUMMARY...
More informationAND STILL GET HIGH QUALITY CARE?
HOW CAN WE REDUCE OUR HEALTH CARE SPENDING AND STILL GET HIGH QUALITY CARE? A Choicework discussion guide from Public Agenda, developed through a collaborative research project with the Kettering Foundation
More informationExpanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
More information